RT Journal Article
SR Electronic
T1 The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.22.22272739
DO 10.1101/2022.03.22.22272739
A1 Thuy P. Nguyen
A1 Quyet Do
A1 Lan T. Phan
A1 Dang D. Anh
A1 Hiep Khong
A1 Thuong V. Nguyen
A1 Luong V. Hoang
A1 Duc V. Dinh
A1 Hung N. Pham
A1 Men V. Chu
A1 Toan T. Nguyen
A1 Quang D. Pham
A1 Tri M. Le
A1 Tuyen N.T. Trang
A1 Thanh T. Dinh
A1 Thuong V. Vo
A1 Thao T. Vu
A1 Quynh B.P. Nguyen
A1 Vuong T. Phan
A1 Luong V. Nguyen
A1 Giang T. Nguyen
A1 Phong M. Tran
A1 Thuan D. Nghiem
A1 Tien V. Tran
A1 Tien G. Nguyen
A1 Tuynh Q. Tran
A1 Linh T. Nguyen
A1 Anh T. Do
A1 Dung D. Nguyen
A1 Son A. Ho
A1 Viet T. Nguyen
A1 Dung T. Pham
A1 Hieu B. Tran
A1 Son T. Vu
A1 Su X. Hoang
A1 Trung M. Do
A1 Xuan T. Nguyen
A1 Giang Q. Le
A1 Ton Tran
A1 Thang M. Cao
A1 Huy M. Dao
A1 Thao T.T. Nguyen
A1 Uyen Y Doan
A1 Vy T.T. Le
A1 Linh P. Tran
A1 Ngoc M. Nguyen
A1 Ngoc T. Nguyen
A1 Hang T.T. Pham
A1 Quan H. Nguyen
A1 Hieu T. Nguyen
A1 Hang L.K. Nguyen
A1 Nguyen V. Trang
A1 Anh T.L. Nguyen
A1 Linh T. Nguyen
A1 Anh P. Nguyen
A1 Nhung T.H. Trinh
A1 Ly T.K. Le
A1 Van T. B. Tran
A1 Mai T. N. Chu
A1 My H. Phan
A1 My H. Phan
A1 Hoa T. H. Nguyen
A1 Vinh T. Tran
A1 Mai T.N. Tran
A1 Truc T.T. Nguyen
A1 Phat T. Ha
A1 Hieu T. Huynh
A1 Khanh D. Nguyen
A1 Nghia H.T. Duong
A1 Ung T. Thuan
A1 Chung C. Doan
A1 May
A1 Si M. Do
YR 2022
UL http://medrxiv.org/content/early/2022/03/23/2022.03.22.22272739.abstract
AB Background Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminum hydroxide adjuvant. In a Phase 1 and 2 studies, (NCT04683484) the vaccine was found to be safe and induce a robust immune response in healthy adult participants.Methods We conducted a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and protective efficacy of the Nanocovax vaccine against Covid-19 in approximately 13,007 volunteers aged 18 years and over. The immunogenicity was assessed based on Anti-S IgG antibody response, surrogate virus neutralization, wild-type SARS-CoV-2 neutralization and the types of helper T-cell response by intracellular staining (ICS) for interferon gamma (IFNg) and interleukin-4 (IL-4). The vaccine efficacy (VE) was calculated basing on serologically confirmed cases of Covid-19.Findings Up to day 180, incidences of solicited and unsolicited adverse events (AE) were similar between vaccine and placebo groups. 100 serious adverse events (SAE) were observed in both vaccine and placebo groups (out of total 13007 participants). 96 out of these 100 SAEs were determined to be unrelated to the investigational products. 4 SAEs were possibly related, as determined by the Data and Safety Monitoring Board (DSMB) and investigators. Reactogenicity was absent or mild in the majority of participants and of short duration. These findings highlight the excellent safety profile of Nanocovax.Regarding immunogenicity, Nanocovax induced robust IgG and neutralizing antibody responses. Importantly, Anti S-IgG levels and neutralizing antibody titers on day 42 were higher than those of natural infected cases. Nanocovax was found to induce Th2 polarization rather than Th1.Post-hoc analysis showed that the VE against symptomatic disease was 51.5% (95% confidence interval [CI] was [34.4%-64.1%]. VE against severe illness and death were 93.3% [62.2-98.1]. Notably, the dominant strain during the period of this study was Delta variant.Interpretation Nanocovax 25 microgram (mcg) was found to be safe with the efficacy against symptomatic infection of Delta variant of 51.5%.Funding Research was funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of Vietnam; ClinicalTrials.gov number, NCT04922788.Competing Interest StatementSi M. Do, Mai NN Tran, and Bruce May are holders of Nanocovax patent applicationClinical TrialNCT04922788Funding StatementResearch was funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of VietnamAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics commmittee appointed by the Vietnam Ministry of Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors